Induction of clinical response (6–10 weeks) · people with Crohn's disease
Vedolizumab leads to higher induction of clinical response (6–10 weeks) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in adverse events (6–10 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (6–10 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (6–10 weeks) compared with placebo (low certainty).
1 finding from 1 review
Maintenance of clinical remission · people with Crohn's disease
Vedolizumab leads to higher maintenance of clinical remission (52–60 weeks) compared with placebo (high certainty).
1 finding from 1 review
Adverse events (52–60 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in adverse events (52–60 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events (52–60 weeks) · people with Crohn's disease
Vedolizumab showed no clear difference in serious adverse events (52–60 weeks) compared with placebo (low certainty).
1 finding from 1 review
Abdominal pain frequency or change in frequency · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain intensity or change in intensity · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
Treatment success as defined by the authors · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain frequency or change in frequency · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain intensity (0‐10cm visual analogue scale) · people with Crohn's disease
1 finding from 1 review
Withdrawals due to adverse events · people with Crohn's disease
1 finding from 1 review
Treatment success as defined by the authors · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain frequency or change in pain frequency · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with Crohn's disease
1 finding from 1 review
Withdrawals due to adverse events · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment success as defined by the authors · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain frequency or change in pain frequency · people with Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · people with Crohn's disease
1 finding from 1 review